BCR::ABL1 Fusion Transcript, t(9;22)(q34;q11.2), RT-PCR
Print
| WSLH Department: | Cytogenetics |
| WSLH Test Code: | 887M31 |
| Day(s) Performed: | Monday-Friday 7:45 AM - 4:30 PM, Saturday 7:45 AM - 12:00 PM |
| Turn-around Time: | Approximately 2-4 days. (Reports are issued Monday-Friday 7:45 AM - 4:30 PM) |
| Recommended Uses: | Detection of BCR::ABL1 fusion transcripts associated with CML and ALL. Aids in diagnosis of hematologic disorders. |
| Contraindications: | |
| Additional Tests Performed: |
| Patient Preparations: | |
| Specimen Requirements: | **1.0-2.0 ml early aspirate bone marrow OR **5-10 ml whole blood collected in EDTA vacuum type tube |
| Specimen Handling & Transport: | Store and transport specimens at room temperature (may transport with coolant during hot weather, >85 degrees F). Specimens must be received by the laboratory within 24 hours of collection. If specimen has to be stored more than 48 hours, refrigerate at 2°C to 8°C. |
| Collection Kit/Container: | |
| Collection Instructions: | **Bone marrow: 1.0-2.0ml bone marrow from the first or second aspirate. It is important that material submitted for cytogenetic analysis is from an early aspirate. Later aspirates are likely to be diluted with blood and the abnormal clone may not be detected. Transfer the marrow to a sterile, EDTA vacuum type tube for delivery to State Lab. **Blood: Draw blood using aseptic techniques into a sterile EDTA vacuum type tube(s). Invert tube(s) to mix. If using larger tubes, draw full tube(s) of blood to avoid over-treatment with anti-coagulant. |
| Unacceptable Conditions: | Sample must not be frozen or hemolyzed. Please note that sodium heparin is known to inhibit PCR. Plasma and serum are not acceptable. |
| Requisition Form: |
Cytogenetics Lab Neoplasia Diagnosis Form #132
|
| Required Information: | Laboratory regulations require the following minimum information to be provided on the requisition form for a specimen to be accepted for testing: Patient name or unique identifier; date and time of collection, patient date of birth and sex, specimen type/site of collection, test request(s), reason for referral, clinician name and UPIN/NPI, and address for reporting results. Please be certain that name/identifier on the form matches that on the specimen label. |
| Results Include: | BCR::ABL1 fusion detected/not detected. Splice breakpoints reported. |
| Limitations: | This assay is designed to detect e13a2 & e14a2 major (p210) and e1a2 minor (p190) BCR::ABL1 fusion transcripts. Rare BCR::ABL1 fusions involving other breakpoints are not detectable by this test. This assay will not detect BCR::ABL1 fusion gene transcripts below the limit of detection (LOD). The analytical sensitivity (LOD) of this assay has been determined at 1 BCR::ABL1 positive cell in 1,000 cells, or 0.1%. This test is not intended to detect minimal residual disease. Failure to identify an abnormal clone by RT-PCR does not rule out the presence of other abnormalities in the specimen. |
| Additional Tests Recommended: | |
| Additional Comments: |
| Methodology: | Reverse transcription of mRNA is performed using translocation specific primers. The resulting cDNA is PCR amplified with multiple primers designed to detect the following BCR::ABL1 fusion gene transcripts: Major (p210) e13a2, e14a2 and minor (p190) e1a2. The PCR amplification products are size separated by agarose gel electrophoresis, stained, and visualized. An internal control as well as a positive control, a negative control, and a no template control are run with each assay. |
| Includes: | Reverse-Transcription PCR for the detection of Major (p210) and minor (p190) BCR/ABL1 fusion transcripts associated with t(9;22)(q34;q11.2) recurrent in CML and ALL. |
| CPT Code: | 81206, 81207 |
| Price: | For pricing information, please call 608-262-0402. |